Jim Gallagher on Muck Rack

Jim Gallagher

St. Louis
As seen in: Daily Mail, Financial Times, Irish Daily Mail, The Daily Mirror, The Times, The Seattle Times, The Scotsman, Ayrshire Post, LSE Connect, blogs.lse.ac.uk and
Reporter at the St. Louis Post-Dispatch
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jim

Contact Jim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase 3 Ixo-Vec Program Advances

|
By Jim Gallagher
| Retinal Physician
The phase 3 development program for ixoberogene soroparvovec (ixo-vec; Adverum Biotechnologies) in neovascular age-related macular degeneration (nAMD) is moving forward, according to Deepak Sambhara, MD, FASRS, who presented an overview of the program at the 2026 Retina World Congress. Ixo-vec is designed as a clinic-based intravitreal gene therapy using an AAV7m8 vector engineered to cross the internal limiting membrane and transduce retinal cells.
Open in Who Shared Issue with article?

Diagnosing and Treating Ocular Lymphoma

|
By Jim Gallagher
| Retinal Physician
A patient with floaters and blurred vision is treated repeatedly for presumed uveitis. Steroids help, but only temporarily. As inflammation recurs, suspicion shifts slowly away from benign inflammatory disease toward a more serious masquerade. For vitreoretinal specialists, this scenario is often the first clinical clue of primary vitreoretinal lymphoma (PVRL).
Open in Who Shared Issue with article?

Can Gene Therapy Deliver Durability?

|
By Jim Gallagher
| Retinal Physician
For retina specialists managing patients with neovascular age-related macular degeneration (nAMD), the question is no longer whether anti-VEGF therapy can preserve vision, but whether treatment can be delivered with fewer injections over longer periods of time. Durability has become a central focus of drug development, particularly for intravitreal gene therapy programs designed to provide sustained intraocular anti-VEGF expression after a single treatment.
Open in Who Shared Issue with article?
See all 644 licensed articles (811 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Jim

Contact Jim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified